"uuid:ID","label","instanceType","description","id","text","name"
"49b2e3a9-e19e-4c6f-a9ed-3b75d1a05d14","","Objective","Main objective","Objective_1","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","OBJ1"
"4c9acf6b-e97d-4df1-8147-0feaaaf8e3d5","","Objective","Safety","Objective_2","To document the safety profile of the xanomeline TTS.","OBJ2"
"a309a6a9-7975-4dce-a34e-1180efeea68a","","Objective","Behaviour","Objective_3","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","OBJ3"
"616a97e2-af64-4537-8ade-9343eeea966b","","Objective","","Objective_4","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","OBJ4"
"ba1f16e0-f2d9-4c91-ac37-396a6eaff65b","","Objective","","Objective_5","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","OBJ5"
"25a08ba8-8217-4ed8-80ee-7e111d2793fe","","Objective","","Objective_6","To assess the treatment response as a function of Apo E genotype.","OBJ6"
